Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1984;3(1):53-74.
doi: 10.1007/BF00047693.

Relationship of tumor leucocytic infiltration to host defense mechanisms and prognosis

Review

Relationship of tumor leucocytic infiltration to host defense mechanisms and prognosis

J W Kreider et al. Cancer Metastasis Rev. 1984.

Abstract

The interface between the tumor and the host is often the site of leucocytic infiltration. We will examine the idea that the infiltrating leucocytes of human and experimental tumors are components of the host immunological defense against the tumor, and that the presence of the infiltrate is a marker of favorable prognosis. Leucocytes could infiltrate tumors because of an active immune response, either nonspecific or specifically directed to tumor-associated antigens. Leucocyte influx may also occur because of chemotactic factors secreted by the tumor cells. Some tumors release factors which enhance vascular permeability and permit improved access by leucocytes to the tumor focus. The consequences of leucocytic infiltration include tumor cell cytolysis, cytostasis, or stimulation of proliferation. The present state of our knowledge of the interactions between tumor cells and infiltrating leucocytes precludes broad generalization of mechanisms. Further study will probably reveal that the mechanisms are diverse, and that there are some systems in which immune interactions occur at this interface and others in which they do not.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Natl Cancer Inst. 1979 Jun;62(6):1459-72 - PubMed
    1. Cancer Res. 1983 Jun;43(6):2749-53 - PubMed
    1. Lab Invest. 1964 Sep;13:1080-98 - PubMed
    1. Cell Immunol. 1978 Jun;38(1):76-83 - PubMed
    1. J Clin Invest. 1970 Jun;49(6):1188-99 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources